IMMP vs. SAVA, OPK, CNTA, IMNM, ABVX, ARCT, SPRY, ARQT, OCUL, and ETNB
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Cassava Sciences (SAVA), OPKO Health (OPK), Centessa Pharmaceuticals (CNTA), Immunome (IMNM), ABIVAX Société Anonyme (ABVX), Arcturus Therapeutics (ARCT), ARS Pharmaceuticals (SPRY), Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), and 89bio (ETNB). These companies are all part of the "pharmaceutical preparations" industry.
Cassava Sciences (NASDAQ:SAVA) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Cassava Sciences has a beta of -0.49, indicating that its share price is 149% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.
Cassava Sciences' return on equity of 0.00% beat Immutep's return on equity.
In the previous week, Immutep had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Immutep and 1 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.53 beat Immutep's score of 0.30 indicating that Immutep is being referred to more favorably in the news media.
Immutep received 215 more outperform votes than Cassava Sciences when rated by MarketBeat users. Likewise, 72.43% of users gave Immutep an outperform vote while only 66.43% of users gave Cassava Sciences an outperform vote.
38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 12.2% of Cassava Sciences shares are owned by insiders. Comparatively, 3.1% of Immutep shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Cassava Sciences currently has a consensus target price of $131.00, suggesting a potential upside of 584.79%. Immutep has a consensus target price of $8.50, suggesting a potential upside of 221.97%. Given Immutep's higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Immutep.
Immutep has higher revenue and earnings than Cassava Sciences.
Summary
Immutep beats Cassava Sciences on 10 of the 13 factors compared between the two stocks.
Get Immutep News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
